Overview
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.
Indication
Meloxicam is indicated for the symptomatic treatment of arthritis and osteoarthritis. In addition, it is indicated for the pauciarticular and polyarticular course of Juvenile Rheumatoid Arthritis (JRA) in patients aged 2 years old or above. Off-label uses include the treatment of dental or post-surgical pain. In addition to the above, meloxicam has also been studied in the treatment of neuropathic pain. Meloxicam, in combination with bupivacaine, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.
Associated Conditions
- Dental Pain
- Neuropathic Pain
- Osteoarthritis (OA)
- Pain, Inflammatory
- Pauciarticular juvenile rheumatoid arthritis
- Polyarticular juvenile rheumatoid arthritis, chronic or unspecified
- Postoperative pain
- Rheumatoid Arthritis
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2021/02/25 | N/A | Completed | |||
2021/02/23 | Phase 4 | Terminated | |||
2021/01/26 | Phase 3 | UNKNOWN | |||
2020/07/29 | Phase 1 | UNKNOWN | Daewoong Pharmaceutical Co. LTD. | ||
2020/07/21 | Phase 2 | UNKNOWN | Shanghai University of Traditional Chinese Medicine | ||
2020/03/26 | Phase 1 | UNKNOWN | Beijing Tongren Hospital | ||
2019/10/03 | Phase 2 | Completed | |||
2019/07/01 | Not Applicable | Completed | |||
2019/03/29 | Phase 3 | Completed | |||
2018/09/25 | Phase 1 | Completed |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Strides Pharma Science Limited | 64380-716 | ORAL | 15 mg in 1 1 | 5/28/2021 | |
| Denton Pharma, Inc. DBA Northwind Pharmaceuticals | 70934-010 | ORAL | 7.5 mg in 1 1 | 2/1/2023 | |
| Denton Pharma, Inc. DBA Northwind Pharmaceuticals | 70934-011 | ORAL | 15 mg in 1 1 | 1/10/2023 | |
| Zydus Lifesciences Limited | 65841-050 | ORAL | 7.5 mg in 1 1 | 10/18/2022 | |
| RedPharm Drug, Inc. | 67296-0823 | ORAL | 15 mg in 1 1 | 2/15/2023 | |
| STAT Rx USA LLC | 42549-604 | ORAL | 7.5 mg in 1 1 | 2/23/2012 | |
| Boehringer Ingelheim Animal Health USA Inc. | 0010-6014 | ORAL | 0.05 g in 100 mL | 5/2/2025 | |
| Aphena Pharma Solutions - Tennessee, LLC | 71610-583 | ORAL | 7.5 mg in 1 1 | 3/3/2022 | |
| Bryant Ranch Prepack | 71335-1956 | ORAL | 15 mg in 1 1 | 8/16/2021 | |
| Zydus Lifesciences Limited | 65841-051 | ORAL | 15 mg in 1 1 | 10/18/2022 |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Meloxicam Dispersible Tablets | 国药准字H20020245 | 化学药品 | 片剂 | 8/10/2020 | |
| Meloxicam Dispersible Tablets | 国药准字H20010108 | 化学药品 | 片剂 | 7/9/2020 | |
| Meloxicam Tablets | 国药准字H20020431 | 化学药品 | 片剂 | 4/24/2020 | |
| Meloxicam Tablets | 国药准字H20020141 | 化学药品 | 片剂 | 7/24/2020 | |
| Meloxicam Tablets | 国药准字H20133188 | 化学药品 | 片剂 | 3/23/2023 | |
| Meloxicam Tablets | 国药准字H20020217 | 化学药品 | 片剂 | 4/28/2020 | |
| Meloxicam Tablets | 国药准字H20010203 | 化学药品 | 片剂 | 8/17/2020 | |
| Meloxicam Tablets | 国药准字H20020369 | 化学药品 | 片剂 | 1/21/2020 | |
| Meloxicam Tablets | 国药准字H20030644 | 化学药品 | 片剂 | 12/6/2019 | |
| Meloxicam Tablets | 国药准字H20020222 | 化学药品 | 片剂 | 11/14/2019 |
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| MOBIC meloxicam 15mg tablet blister pack | 77695 | Medicine | A | 2/23/2001 | |
| MOBIC meloxicam 7.5mg tablet blister pack | 77694 | Medicine | A | 2/23/2001 | |
| MELOXICAM TIH meloxicam 15mg tablet blister pack | 385064 | Medicine | A | 6/23/2022 | |
| MELOXICAM SPR meloxicam 7.5mg tablet blister pack | 385065 | Medicine | A | 6/23/2022 | |
| MELOXICAM-WGR meloxicam 15 mg capsule blister pack | 232581 | Medicine | A | 9/23/2015 | |
| MELOXICAM VIATRIS meloxicam 15 mg tablet blister pack | 389283 | Medicine | A | 10/7/2022 | |
| MELOXICAM TIH meloxicam 7.5mg tablet blister pack | 385063 | Medicine | A | 6/23/2022 | |
| MELOXICAM-WGR meloxicam 15 mg tablets blister pack | 389372 | Medicine | A | 10/7/2022 | |
| MOBIC meloxicam 7.5mg capsule blister pack | 77698 | Medicine | A | 2/23/2001 | |
| MELOXICAM CH 7.5 meloxicam 7.5 mg tablets blister pack | 189817 | Medicine | A | 4/30/2012 |
Help Us Improve
Your feedback helps us provide better drug information and insights.